

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 39.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.392, 93.893, National Institutes of Health, HHS)

Dated: February 7, 1997.

LaVerne Y. Stringfield,

*Committee Management Officer, NIH.*

[FR Doc. 97-3633 Filed 2-12-97; 8:45 am]

BILLING CODE 4140-01-M

### Prospective Grant of Exclusive License: Diagnostic Test for Alzheimer's Disease

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patents and patent applications referred to below to NeuroLogic, Inc. of Washington, D.C. The patents and patent applications to be licensed are U.S. Patent No. 5,580,748 issued December 3, 1996 (U.S. Patent Application Serial No. 08/056,456 filed May 3, 1993), entitled "Cell Test for Alzheimer's Disease," and all continuation applications, divisional applications, continuation-in-part applications, and foreign counterpart applications related to U.S. Patent Application Serial No. 08/056,456.

**SUPPLEMENTARY INFORMATION:** The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Alzheimer's disease (AD) represents the fourth leading cause of death in the United States, killing over 100,000 annually, and afflicting some 4 million Americans and is projected to affect

over 14 million by the year 2050. Various reports indicate that the incidence of Alzheimer's disease increases with age and estimate that the prevalence of AD in people over 80 years of age is between 20 and 50%. Under currently available technology AD can only be positively diagnosed by pathological examination of brain tissue during autopsy in conjunction with a clinical history of dementia.

Present efforts to diagnosis the disease have been generally directed to the identification and detection of molecules present in blood samples or in cerebral spinal fluid (CSF). Current tests for the detection of Alzheimer's disease have met with varying degrees of commercial success. The proposed technology involves the identification of Alzheimer's disease utilizing fibroblast cells. The method consists of: Measuring the presence or absence of a specific potassium channel, measuring the effect of potassium channel blockers specific for the 113 pS potassium channel on intracellular calcium levels, measuring the increase of intracellular calcium in response to an activator of intracellular calcium release in the cells of a patient, and measuring the amount of the G-protein, cp20.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to: Stephen L. Finley, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852; Telephone: (301) 496-7056, ext. 215; Facsimile: (301) 492-0220. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before April 14, 1997, will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 4, 1997.

Barbara M. McGarey,

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 97-3530 Filed 2-12-97; 8:45 am]

BILLING CODE 4140-01-M

### Substance Abuse and Mental Health Services Administration

#### Office for Women's Services; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Advisory Committee for Women's Services of the Substance Abuse and Mental Health Services Administration (SAMHSA) in February 1997.

The meeting of the Advisory Committee for Women's Services will include a discussion of policy and program issues relating to women's substance abuse and mental health service needs; the SAMHSA fiscal year 1998 budget; resolutions adopted at the Committee's September meeting; consideration of September meeting minutes; and other policy issues.

A summary of the meeting and/or a roster of committee members may be obtained from: Pamela J. McDonnell, Executive Secretary, Advisory Committee for Women's Services, Office for Women's Services, SAMHSA, Parklawn Building, Room 13-99, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443-5184.

Substantive information may be obtained from the contact whose name and telephone number is listed below.

*Committee Name:* Advisory Committee for Women's Services.

*Meeting Date(s):* February 24, 1997.

*Place:* Room 12-94, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.

*Open:* February 24, 2:00 p.m. to 4:00 p.m.

*Contact:* Pamela J. McDonnell, Room 13-99, Parklawn Building, Telephone: (301) 443-5184.

This notice is being published less than 15 days prior to the meeting due to the urgent need to resolve pending issues before a full meeting can be scheduled.

Dated: February 7, 1997.

Jeri Lipov,

*Committee Management Officer, Substance Abuse and Mental Health Services Administration.*

[FR Doc. 97-3586 Filed 2-12-97; 8:45 am]

BILLING CODE 4162-20-P

### DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4200-N-24]

#### Notice of Proposed Information Collection for Public Comment

**AGENCY:** Office of the Assistant Secretary for Policy Development and Research, HUD.

**ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below